The identification of AGBL4 and MMP-1 not only deepens our understanding of the molecular dynamics of GBM but also highlights their involvement in inflammatory processes that may contribute to tumor aggressiveness, suggesting the potential of AGBL4 and MMP-1 as strategic targets for gene-directed therapy, as well as advocating for the development of targeted inhibitors against these proteins as a promising new direction for therapeutic intervention in glioma treatment. This evidence concerns the gene MMP1 and central nervous system cancer.